

**NEWS RELEASE**

Solna, October 17<sup>th</sup>, 2016

## **The Spirit and Vision of Eurocine Vaccines - Board Directors in Interview**

**While the team of Eurocine Vaccines is working intensely with the upcoming clinical trial and recently represented the company in Japan, the board directors share their views on the spirit and vision of the company.**

Being a small and efficient organization, the success of the company is dependent on a good relationship and involvement of the board directors and their expertise. Now, they step forward and share their work, passion and commitment in a short video on Eurocine Vaccines.



Hear their story, why they believe in both the product and organization and what thrills them to take part on this journey into the future of vaccination.

### **For more information, please contact:**

Hans Arwidsson, Ph.D., MBA  
CEO of Eurocine Vaccines AB  
hans.arwidsson@eurocine-vaccines.com  
+46 70 634 0171

### **About Eurocine Vaccines**

Eurocine Vaccines is a publicly listed company, using its clinically validated technology Endocine™ to develop a patent protected nasal influenza vaccine for children. Within the market for influenza vaccines, children is the fastest growing segment. This is due to the recommendation by the WHO to vaccinate children against influenza. The company's main project, the nasal quadrivalent influenza vaccine Immunose™ FLU, is planned to enter clinical development in the fall of 2016.

The company plans to license the product to partners for further development and commercialization.

Eurocine Vaccines, EUCI, is traded at Aktietorget, XSAT.